How CAR T-Cell Therapy Fights Cancer
CAR T-cell therapy reprograms a patient's own immune cells to hunt and destroy cancer. Here's how this revolutionary treatment works, which cancers it targets, and what its limits are.
The Immune System, Reprogrammed
For most of medical history, cancer treatment meant cutting, burning, or poisoning tumors — surgery, radiation, or chemotherapy. CAR T-cell therapy is something fundamentally different: it turns a patient's own immune system into a precision weapon, engineering white blood cells to recognize and destroy cancer cells that the body would otherwise ignore.
First approved by the U.S. Food and Drug Administration in 2017, CAR T-cell therapy has since offered complete remissions to patients with some of the most treatment-resistant blood cancers. Understanding how it works reveals both the extraordinary promise — and the very real limits — of this approach.
What Is a CAR T Cell?
CAR stands for chimeric antigen receptor — a synthetic protein that scientists attach to the surface of T cells, the immune system's primary cancer-killing cells. The word "chimeric" refers to the receptor's hybrid nature: it is assembled from fragments of different proteins, combining an antibody's ability to recognize a specific target with a T cell's internal machinery for launching an attack.
In healthy immunity, T cells can only attack targets they have already "learned" to recognize. Cancer cells often evolve ways to disguise themselves and escape that recognition. The CAR bypasses this limitation entirely: it is engineered to lock onto a specific protein (an antigen) found on the surface of cancer cells, triggering the T cell to kill regardless of the tumor's evasion strategies.
How the Treatment Works: Step by Step
CAR T-cell therapy is highly personalized — each treatment is made from the individual patient's own cells. The process unfolds in several stages:
- Collection (apheresis): Blood is drawn from the patient and passed through a machine that separates and removes T cells, returning the rest of the blood to the body.
- Genetic engineering: In a specialized laboratory, scientists use a modified virus to insert the gene for the CAR protein into the T cells' DNA. The cells then begin producing the receptor on their surface.
- Expansion: The modified cells are grown in the lab until they number in the hundreds of millions — enough for a therapeutic dose. This can take two to four weeks.
- Infusion: The patient typically receives a short course of chemotherapy to make room for the new cells, then the CAR T cells are infused back into the bloodstream through an IV — a process that takes as little as 30 minutes.
- Attack: Inside the body, CAR T cells multiply further, circulate, and bind to cancer cells carrying their target antigen. Upon binding, they release toxic molecules that destroy the tumor cell — and then move on to the next one.
Which Cancers Can It Treat?
As of 2025, the FDA has approved seven CAR T-cell products, all targeting blood cancers. Approved indications include:
- Acute lymphoblastic leukemia (ALL) in children and young adults
- Large B-cell lymphoma and other non-Hodgkin lymphomas
- Multiple myeloma
- Mantle cell lymphoma
Researchers are actively investigating whether the approach can be extended to solid tumors — breast, lung, and brain cancers — but these have proven far more difficult to crack, in part because solid tumors create a hostile microenvironment that suppresses immune cells.
How Effective Is It?
The results in blood cancers can be striking. According to research published in peer-reviewed journals, CAR T cells targeting the CD19 protein achieve complete response rates of 71–81% in patients with relapsed or refractory B-cell acute lymphoblastic leukemia — patients who had typically already failed multiple other treatments. For multiple myeloma, certain CAR T products have shown overall response rates as high as 98% in clinical trials.
However, as the American Cancer Society notes, initial remission does not always mean a lasting cure. Long-term survival rates are considerably lower than initial response rates, with relapse occurring in up to 60% of patients over time.
Risks and Side Effects
CAR T-cell therapy carries serious risks. The most dangerous is cytokine release syndrome (CRS) — a systemic inflammatory reaction triggered when billions of engineered T cells activate at once, flooding the body with immune signaling molecules called cytokines. Symptoms range from fever and fatigue to life-threatening organ failure.
A second major risk is immune effector cell-associated neurotoxicity syndrome (ICANS), which can cause confusion, seizures, and in rare cases brain swelling. Oncology centers that administer CAR T therapy must be equipped to recognize and treat both conditions rapidly, typically with the anti-inflammatory drug tocilizumab and corticosteroids.
The financial toxicity is also significant: the cost of CAR T-cell products alone ranges from $300,000 to $475,000, with total treatment costs often exceeding $500,000 when hospitalization is included, according to data from the National Cancer Institute.
What Comes Next
Scientists are working to overcome current limitations on several fronts. "Off-the-shelf" allogeneic CAR T cells — made from healthy donor T cells rather than the patient's own — could dramatically cut costs and waiting times. Researchers are also developing next-generation CARs that target multiple antigens simultaneously, reducing the chance that cancer cells escape by losing a single target protein.
Perhaps most ambitiously, early trials are testing CAR T cells against autoimmune diseases such as lupus and multiple sclerosis — conditions where the immune system attacks the body's own tissues. If successful, the same principles that make these cells formidable cancer killers could be redirected to calm an overactive immune response instead.
What was once a last-resort experimental treatment for a handful of leukemia patients is now reshaping how medicine thinks about the relationship between immunity and disease.
